These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11559910)

  • 1. Inaccurate estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening.
    Hackshaw AK; Wald NJ
    Prenat Diagn; 2001 Sep; 21(9):741-6. PubMed ID: 11559910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome.
    Lam YH; Lee CP; Sin SY; Tang R; Wong HS; Wong SF; Fong DY; Tang MH; Woo HH
    Prenat Diagn; 2002 Aug; 22(8):730-5. PubMed ID: 12210586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy.
    Spencer K
    Prenat Diagn; 2002 Dec; 22(13):1229-32. PubMed ID: 12478639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening.
    Hackshaw A; Wald N
    Prenat Diagn; 2002 Nov; 22(11):1051-3. PubMed ID: 12424775
    [No Abstract]   [Full Text] [Related]  

  • 8. Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited.
    Spencer K
    Prenat Diagn; 2002 Oct; 22(10):874-6. PubMed ID: 12378568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical strategies in contingent sequential screening for Down syndrome.
    Benn P; Wright D; Cuckle H
    Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population.
    Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid-specific lectin immunoassay.
    Spencer K; Talbot JA; Abushoufa RA
    Prenat Diagn; 2002 Aug; 22(8):656-62. PubMed ID: 12210572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the value of reporting partial screening results in prenatal screening for Down syndrome.
    Hackshaw AK; Wald NJ
    Prenat Diagn; 2001 Sep; 21(9):737-40. PubMed ID: 11559909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The best marker combination using the integrated screening test approach for detecting various chromosomal aneuploidies.
    Maymon R; Sharony R; Grinshpun-Cohen J; Itzhaky D; Herman A; Reish O
    J Perinat Med; 2005; 33(5):392-8. PubMed ID: 16238533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined first- and second-trimester screening for Down syndrome: an evaluation of proMBP as a marker.
    Rode L; Wøjdemann KR; Shalmi AC; Larsen SO; Sundberg K; Nørgaard-Pedersen B; Christiansen M; Tabor A
    Prenat Diagn; 2003 Jul; 23(7):593-8. PubMed ID: 12868091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies.
    Spencer K
    Prenat Diagn; 2001 Jun; 21(6):445-7. PubMed ID: 11438946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of first trimester, second trimester and integrated Down's syndrome screening results in unaffected pregnancies.
    Canini S; Prefumo F; Famularo L; Venturini PL; Palazzese V; De Biasio P
    Clin Chem Lab Med; 2002 Jun; 40(6):600-3. PubMed ID: 12211655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early vaginal bleeding and first-trimester markers for Down syndrome.
    De Biasio P; Canini S; Crovo A; Prefumo F; Venturini PL
    Prenat Diagn; 2003 Jun; 23(6):470-3. PubMed ID: 12813760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome.
    Laigaard J; Spencer K; Christiansen M; Cowans NJ; Larsen SO; Pedersen BN; Wewer UM
    Prenat Diagn; 2006 Oct; 26(10):973-9. PubMed ID: 16892462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.